DigniCap™ System Chosen for Cancer Patients at CircleBath Hospital

Clinically-Proven Therapy Prevents Chemo-Related Hair Loss with Greater Comfort and Precision

Residents of Bath and Bristol Now Have Access to New State-of-the-Art Cancer Care Therapy ~

LONDON (February 25, 2013)-The DigniCap™ System, considered to be the most scientifically-advanced scalp-cooling treatment available for reducing chemotherapy-related hair loss in men and women today, has been chosen by CircleBath Hospital as its preferred hair-loss treatment option for use in its oncology practice. Available now for CircleBath Hospital patients in Bath and surrounding communities, DigniCap is the only system to offer scalp-cooling above freezing with patented, built-in temperature sensors and a precision cooling mechanism that allows for gradual and highly tolerable scalp temperature fluctuations.

The DigniCap™ System, developed by Dignitana, a world leader in scalp-cooling technology, is a safe, gentle and effective treatment for avoiding hair loss related to chemotherapy. The system continuously monitors temperature to ensure comfort and consistent application of the treatment. Caps are specifically designed so that the ears remain uncovered for added comfort and normal hearing during the process, and the user-friendly system features an intuitive, touch-screen control panel.

Considered "one of the finest hospitals in Britain," CircleBath serves residents of Bath, Bristol and the surrounding communities. After personally testing a number of other available methods of scalp-cooling, the cancer treatment specialist nurses at CircleBath chose to offer the DigniCap ™ System, based on its superior tolerability and efficacy. DigniCap is the first scalp cooling system that can be offered with clinical evidence, confidence and consistent results at temperatures above freezing, which makes for a less stressful, and much more comfortable patient experience.

"We researched, deliberated and compared clinical and technical aspects of several scalp-cooling treatments before making our final decision," said Sandra Jones, Lead Nurse for CircleBath Hospital Oncology. "Then we decided that we needed to try the caps ourselves before offering them to our patients. DigniCap was eminently more comfortable and user-friendly. Add to that the assurance of clinically proven safety, and there was really no debate-DigniCap was our unequivocal choice. Our patients deserve only the best."

Clinical results show that eight out of ten women in Europe and Asia who used the DigniCap™ System during chemotherapy retained their hair. Additional trials at leading medical centers around the world have proven the system to be a viable alternative for both women and men of diverse ethnicities. Further clinical results from investigations of the efficacy of scalp cooling with the DigniCap™ System in both the U.S. and the U.K. will be presented at medical conferences and in publications throughout 2013.

"At CircleBath, patients know they are always getting the best treatment possible," said Martin Waleij, CEO of Dignitana, maker of the DigniCap™ System. "We are proud they have chosen to offer their patients the DigniCap™ System-a 21st Century solution for a 21st Century healthcare establishment-it is an honour to be able to add CircleBath Hospital to the growing list of top medical establishments around the world that include the DigniCap™ System in their comprehensive approach to cancer care."

For more information about the DigniCap™ System offered at Circle Health's CircleBath Hospital please email enquiries@circlebath.co.uk.

About Circle Health

Circle is the largest partnership of healthcare professionals in Europe and because consultant and healthcare professionals who work for Circle co-own the facilities they work in, they are empowered to put patients first in everything they do. Our founding belief is that by combining clinical excellence-the best doctors, nurses and medical care-with a superb patient experience-a calming environment and five-star hospitality-patients will be more relaxed and recover faster. And our charges are no more expensive than other private hospitals.

About Dignitana AB (publ)
Dignitana AB, a Swedish medical device company, listed on the OMX Nasdaq First North Stockholm, focused on the patented DigniCap™ System, a medical device for preventing hair-loss in chemotherapy patients and for technologies within the area of medical cooling.

For more information visit www.dignitana.com

Dignitana installs the first DigniCap Delta Scalp Cooling System in Rome

Dignitana ABmanufacturer of The DigniCap® Scalp Cooling System, has announced installation of the first DigniCap Delta at the prestigious Gemelli University Hospital in Rome, Italy last month.


Dignitana Promotes Scalp Cooling at Supportive Care Conference

Dignitana ABworld leader in clinically superior scalp cooling technology, is co-sponsoring a scalp cooling session at the Multinational Association for Supportive Care in Cancer (MASCC) Annual Meeting, held June 21 - 23 in San Francisco, California.


Kommuniké från Dignitana AB årsstämma 2019

Dignitana AB, tillverkare av Dignicap®scalp Cooling system, höll idag årsstämma i bolagets lokaler på traktorgränden 3 i Lund. Stämman beslutade i enlighet med samtliga förslag som styrelsen och aktieägare lagt fram. Nedan följer en sammanfattning av de beslut som fattats. 


Communication from the Dignitana AB Annual General Meeting 2019

Dignitana AB, manufacturer of The DigniCap® Scalp Cooling System, has today held an Annual General Meeting at the company's premises at Traktorgränden 3 in Lund. In all the proposed cases, the AGM resolved in accordance with the Board's proposal. Below is a summary of the decisions taken. 


Dignitana AB Publishes Q1 2019 Interim Report

Results and financial position

Significant events during the period

  • Sales and other income for the period amounted to 10,106 TSEK, $1,102 KUSD, an increase of 69 percent compared to the same period in 2018 and a15 percent quarter over quarter growth compared to fourth quarter 2018.
  • EBITDA amounted to (2,799) TSEK, ($305) KUSD, a 59 percent improvement compared to the same period in 2018.
  • Contracts were signed for 22 locations globally, bringing the total number of sites in the U.S. to 125 in 29 states at the close of first quarter.
  • Dignitana announced receipt of CE Marking approval for European sales of the new DigniCap Delta device.
  • As a result of the rights and directed equity issues in December, Dignitana now has 48,599,155 shares registered at Swedish Companies Registration Office.
  • Dignitana announced a partnership with oneservice GmbH, a global provider of specialty technical services, to provide service and maintenance to facilities offering DigniCap in Europe.

Dignitana Leadership Efforts Prompt Landmark Legislation

Dignitana AB (publ)manufacturer of The DigniCap® Scalp Cooling System, announces that HB3984, the bill providing coverage for scalp cooling that the company initiated in February with Texas State legislators, was passed in the Texas House of Representatives on Friday. The Bill now moves to the Senate where it will be introduced by Sen. Angela Paxton. Once passed in the Senate, the Bill then requires approval by Texas Governor Greg Abbott before being signed into law.


Kallelse till årsstämma i Dignitana AB (publ)

Aktieägarna i Dignitana AB (publ), 556730-5346("Bolaget") kallas härmed till årsstämma onsdag den 15 maj 2019 kl. 9.00 i Bolagets lokaler, Traktorgränden 3, i Lund.


Notice of Annual General Meeting of Dignitana AB (publ)

Aktieägarna i Dignitana AB (publ), 556730-5346("Bolaget") kallas härmed till årsstämma onsdag den 15 maj 2019 kl. 9.00 i Bolagets lokaler, Traktorgränden 3, i Lund.


Rättelse: Felaktig MAR-klassificering i tidigare pressmeddelande

Dignitana AB issues a rättelse i pressmeddelande "Dignitana AB publicerar årsredovisningen för 2018." Rättelsen avser att pressmeddelandet var felaktigt klassat som MAR och innehöll därför stycket som följer:


Correction: Incorrect MAR Classification in previous press release

Dignitana AB issues a correction in press release "Dignitana AB publishes the annual report for 2018." The correction means that the press release was incorrectly classified as MAR and therefore contained the paragraph as follows:


Dignitana AB publicerar årsredovisningen för 2018

Lund, Sweden - 12 April 2019 - Dignitana AB offentliggör härmed årsredovisningen avseende 2018. Årsredovisningen finns som bilaga till detta pressmeddelande samt går att ladda ner från hemsidan, www.dignitana.se. Det går även att beställa en utskriven version via investorrelations@dignitana.com.


Dignitana AB Publishes Annual Report for 2018

Lund, Sweden - 12 April 2019 - Dignitana AB hereby publishes the annual report for 2018. The Annual Report is attached to this press release and will be posted today on the Dignitana website. You can also order a printed version via investorrelations@dignitana.com.


Dignitana AB Receives CE Marking for Next Generation DigniCap Delta to Reduce Hair Loss from Chemotherapy

Dignitana AB (publ), manufacturer of The DigniCap® Scalp Cooling System, today announced receiving CE Marking approval for European sales of DigniCap Delta, the next generation scalp cooling device. An advanced and redesigned model of the 2015 FDA-cleared DigniCap Scalp Cooling System, DigniCap Delta features a new single patient use cap system consisting of a flexible Cooling Wrap and an adjustable Thermal Cap to optimize scalp cooling outcomes and ease-of-use for patients and nurses. The streamlined DigniCap Delta is 54 percent smaller than the current model and the intuitive interface provides up to 80 percent reduction in nursing time per patient infusion versus the existing device.


Dignitana CEO William Cronin to Speak at Aktiedagen Stockholm

Dignitana AB announces that Chief Executive Officer William Cronin will speak at Aktiedagen Stockholm on 19 March 2019 at 15:00 CET.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär